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Abstract Hypertrophic cardiomyopathy (HCM) was the
first inherited heart disease to be characterized at the
molecular genetic level with the demonstration that it is
caused by mutations in genes that encode different
components of the cardiac sarcomere. Early functional in
vitro studies have concluded that HCM mutations cause a
loss of sarcomere mechanical function. Hypertrophy would
then follow as a compensatory mechanism to raise the work
and power output of the affected heart. More recent in vitro
and mouse model studies have suggested that HCM
mutations enhance contractile function and myofilament
Ca2+ sensitivity and impair cardiac myocyte energetics. It
has been hypothesized that these changes may result in
cardiac myocyte energy depletion due to inefficient ATP
utilization and also in altered myoplasmic Ca2+ handling.
The problems encountered in reaching a definitive answer
on the effects of HCM mutations are discussed. Though
direct analysis of the altered functional characteristics of
HCM human cardiac sarcomeres has so far lagged behind
the in vitro and mouse studies, recent work with mechan-
ically isolated skinned myocytes and myofibrils from
affected human hearts seem to support the energy depletion
hypothesis. If further validated in the human heart, this
hypothesis would identify tractable therapeutic targets that
suggest that HCM, perhaps more than any other cardiomy-
opathy, will be amenable to disease-modifying therapy.
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Familial hypertrophic cardiomyopathy (HCM) is an auto-
somal dominant inherited heart disease, which results in
hypertrophy of the left ventricle in the absence of other
cardiac or systemic disease (such as hypertension or aortic
stenosis). It is characterized morphologically by left
ventricular wall and septal hypertrophy, resulting in a
decreased left ventricle volume. Obstruction of the left
ventricular outflow tract is present at rest in approximately
25% of patients and in a higher proportion during exercise.
Histologically, areas of myocyte disarray and interstitial
fibrosis are characteristic of the disease. Although systolic
contractility is most often preserved and features of hyper-
contractility are observed at the whole heart level, outflow
obstruction and impaired relaxation can cause progressive
heart failure and increased incidence of ventricular arrhyth-
mias can lead to sudden cardiac death.
Molecular Basis of HCM: A Disease Intrinsic
to the Cardiac Sarcomere
In 1989, HCM was mapped to chromosome 14 in a
French–Canadian pedigree with autosomal dominant dis-
ease [24]. In 1990, the first missense mutation in a
sarcomeric protein, R403Q in the β-cardiac myosin heavy
chain (β-MyHC), was shown to be responsible for HCM
[17]. Since then, molecular genetics has revealed that HCM
is a complex molecular disease exhibiting both gene and
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allele heterogeneity (multiple disease genes and multiple
mutations) with as many as ten sarcomere-related genes and
more than 400 predominantly missense mutations de-
scribed. Besides β-MyHC, the disease genes (Fig. 1)
encode (1) other thick filament proteins: cardiac myosin-
binding protein-C (cMyBP-C also named cardiac C-
protein) [8, 70], both regulatory (RLC), and essential
(ELC) myosin light chains [48], (2) thin filament proteins:
α-tropomyosin (α-Tm) [65], cardiac troponin T (cTnT)
[65], cardiac troponin I (cTnI) [28], cardiac troponin C
(cTnC) [21, 31], actin [39], and (3) the giant protein titin
[56] which spans both the thick and thin filaments. Most
mutations appear to act as dominant negatives and the
mutant proteins are incorporated into the sarcomere where
they can affect contractile performance (e.g., [12, 10]). A
significant exception to this is likely to be the numerous
truncation mutations in cMyBP-C for which evidence of
haplo-insufficiency has been recently generated [68, 69].
Disease-causing mutations in sarcomere proteins are
detected in 60–70% of HCM-affected individuals and the
most commonly affected genes are MYBPC3 (cMyBP-C)
and MYH7 (β-MyHC), together accounting for approxi-
mately 80% of identified mutations [50].
The prevalence of mutations in sarcomeric proteins has
led to the designation of HCM as primarily a “disease of the
sarcomere” [65, 57, 37]. This raises the question of how
molecular defects in sarcomeric proteins can lead to
myofibril disarray, asymmetric left ventricular hypertrophy,
diastolic dysfunction, and an increased probability of
sudden death. The question is especially challenging also
because the clinical phenotypes among patients with the
same mutation can be rather heterogeneous.
Fig. 1 The cardiac sarcomere. The cardiac sarcomere comprises the
proteins of the thick (red) and thin (blue) filaments, and the giant
protein titin (green) connecting thick filaments to the Z lines.
Mutations in genes encoding each of the proteins labeled in the figure
can cause hypertrophic cardiomyopathy (HCM). The disorder can thus
result from alterations of proteins that have diverse motor, regulatory,
and structural functions. Myosin heavy chain (MyHC), the motor of
cardiac contraction (it is a dimer but in the scheme is depicted as a
single-headed monomer), is made of different domains: the myosin
rod composing the backbone of thick filaments, S2 (arbitrarily
depicted as an elastic spring), connecting the rod to the myosin head,
and the myosin head S1 comprising the actin-binding, catalytic
domain, and the light chain-binding domain (the lever arm of the
motor protein). Most HCM mutations in MyHC are in S1, but HCM-
associated mutations have been also described in both S2 and the
myosin rod. The other thick filament-associated proteins are the
essential (ELC or LC-1) and the regulatory (RLC or LC-2) myosin
light chains bound to the lever arm of S1, and C-protein (or cardiac
myosin binding protein-C, cMyBP-C), a protein with poorly under-
stood regulatory and structural functions. Thin filament proteins
comprise, besides actin, the troponin complex (troponin C, TnC,
troponin I, TnI, and troponin T, TnT) and tropomyosin
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Disease Mechanisms in Sarcomeric HCM: Loss or Gain
of Function?
Since the discovery of the first HCM-associated mutation in
β-MyHC, a large number of biochemical and biophysical
studies have been published on the effects of HCM
mutations on the functional properties of the mutant
proteins. Rather than summarize these many studies for
each gene and mutation, we will focus mostly on results
obtained for the single most extensively studied myosin
mutation, namely, R403Q.
The R403Q mutation replaces a basic arginine residue
with a polar glutamine residue at the base of a highly
conserved actin-binding loop, renamed the cardiomyopathy
loop because of its role in HCM. The effects of this amino-
acid replacement on the properties and functions of myosin
are not predictable either in terms of actin binding or any
change in the energetic cost of contraction.
Early studies of systems containing the R403Q mutant
myosin [12, 61, 32, 55, 15, 53] showed severely diminished
function, whatever sources of mutant protein were used
(biopsies from slow skeletal muscle of HCM patients or
recombinant proteins from different expression systems) and
whatever assays were performed (in vitro motility assays and
acto-myosin ATPase in isolated proteins, force, and shorten-
ing velocity in slow skeletal skinned muscle fibers). On the
basis of these results, it has been hypothesized that HCM is
caused by altered acto-myosin interactions and that the
accompanying loss of sarcomere function drives the hyper-
trophy of the left ventricle [12, 36].
Although intuitively appealing, the “compensatory hyper-
trophy hypothesis” for HCM, has been challenged by a
number of studies on the effects of HCM mutations in
sarcomeric proteins other than β-MyHC and more recent
work on the R403Q mutation. Most (though not all) HCM
mutations in thin filament regulatory proteins (α-Tm, cTnI,
cTnT, cTnC) increase the Ca2+ sensitivity of force generation,
thereby increasing force at submaximal Ca2+ concentrations
that are normal in intact cardiac myocytes (e.g. [10, 41, 14,
45]). In addition, actin filaments, when reconstituted with
regulatory proteins containing some HCM-associated TnT
mutants, show increased velocity of translocation in in vitro
motility assays [33, 60, 23]. Finally, studies of novel systems
containing the R403Q and other HCM-mutant myosins
imply that the mutant proteins have enhanced motor activity
rather than diminished function (e.g., [72, 66, 38]. For
example, using homozygous R403Q myosin isolated from
neonatal transgenic mice (in the α-MyHC backbone) [66]
found higher sliding velocity in an in vitro motility assay
along with higher actin-activated ATPase activity. Evidence
of an apparent gain in motor protein function has been also
obtained from cardiac samples of R403 mutant HCM
patients [27, 7]; see also below).
To reconcile the lack of consistent contractile depression in
HCM, it has been proposed that HCM sarcomere mutations
may lead to increased cost of force production through
inefficient or excessive ATP usage and that this ultimately
results in an energy deficiency that contributes to the
pathogenesis of the disease [2, 3]. The “energy depletion
hypothesis” for HCM is strengthened by the finding that
HCM-like phenotypes have been reported in a variety of
diseases that limit myocardial energy production. Interestingly,
mutations in the γ2 regulatory subunit of AMP-activated
protein kinase, which senses and protects cells from ATP
depletion, cause cardiomyopathy with severe hypertrophy
(more than can be accounted for by the glycogen deposition),
and ventricular pre-excitation [6, 1]. Furthermore, it has been
shown, using nuclear magnetic resonance (31P NMR) spec-
troscopy, that the cardiac phosphocreatine (PCr) to ATP ratio,
a measure of energy status, is reduced in HCM patient hearts
by ~30% compared with controls [11]. The PCr/ATP ratio was
reduced in both those with and without left ventricular
hypertrophy suggesting that energy deficiency is a primary
event rather than a secondary consequence of remodeling.
One of the predicted consequences of the energy
depletion hypothesis for HCM is that reuptake of Ca2+ into
the sarcoplasmic reticulum will be compromised because of
the extreme energy requirements of the cardiac SERCA
pump (Sarco-Endoplasmic Reticulum Calcium ATPase). In
support of this notion, 31P NMR spectroscopy studies in
transgenic mouse models of HCM have shown that the ∆G
of ATP hydrolysis is reduced to a level at which SERCA
function will be compromised [58, 26, 19]. Increased Ca2+
concentrations in specific microdomains would activate
hypertrophy-signaling pathways.
In addition, these proposed mechanisms, predicted to yield
increased cytosolic Ca2+, would be pro-arrhythmic. Also, the
increased myofilament Ca2+ sensitivity, frequently reported in
HCM models, can be related to increased susceptibility to
cardiac arrhythmias [4]. As myofilaments are the major
dynamic buffer of Ca2+ in the sarcoplasm, it is likely that this
will impact on the Ca2+ transient. This, in turn, may lead to
action potential remodeling and further alterations in intracel-
lular Ca2+ handling to create both an arrhythmogenic substrate
and a trigger. In isolated mouse hearts, myofilament Ca2+-
sensitization by drugs or troponin mutations associated with
HCM are reported to induce arrhythmias by (1) shortening the
effective refractory period and the action potential duration,
(2) slowing conduction velocity, and (3) predisposing to early
after-depolarizations and triggered activity [4].
Disparate Models, Disparate Results
Although increased energy cost of tension generation may
be central to the HCM disease process and helps explain
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some unresolved clinical observations [2], the pathways
linking the various genetic defects to the characteristic
human disease phenotype remain largely unknown. Even
the fundamental question of whether these mutations cause
a gain or loss of sarcomere mechanical function remains
unresolved.
The effects of the R403Q mutation on myosin function
show that substantial disagreement exists between early and
subsequent reports on this topic (literature cited above). A
novel report [35] suggests that the functional sequelae of
the R403Q mutation are dependent on the context of the
cardiac myosin isoform, adding further complexity. A
limitation of the original R403Q murine model for HCM
[16] is that the mutation was produced by replacing, by
homologous recombination, the gene of the mouse α-
cardiac MyHC, the predominant myosin isoform in the
postnatal mouse ventricle with the mutant α-cardiac MyHC
R403Q gene. All larger mammals, including humans, have
the slower β-cardiac myosin expressed predominantly in
their ventricles, and the faster α-MyHC is confined to the
atria. Because the α- and β-cardiac MyHC isoforms of all
species are 93% identical in amino-acid sequence, it has
been generally assumed that the different backbones would
have few, if any, consequences for function. This assump-
tion has been tested using a transgenic mouse model in
which the endogenous α-cardiac MyHC was largely
replaced with transgenically encoded β-cardiac MyHC
and comparing the functional properties of R403Q myosin
expressed in an α- or β-backbone [35]. Whereas the
mutation in an α-backbone showed an increase in sliding
velocity in the in vitro motility assay and actin-activated
ATPase activity relative to wild-type α-myosin, confirming
previous findings ([66], see above), the same mutation in a
β-backbone had little effect on motility and a slight
decrease of enzymatic activity relative to wild-type
β-myosin.
Why are there such disparate results on the functional
sequelae of sarcomeric protein mutations associated with
HCM? Answers may lie in the different assessment methods
for protein function and in different sources of mutant proteins.
Function of sarcomeric protein has been assessed (1) in
vitro in isolated proteins or (2) in situ in myocytes (and
other isolated muscle models) or in intact hearts expressing
the mutant proteins. Sarcomeric protein dysfunction can be
studied in situ by measuring the mechanical parameters of
contractility in myocytes or diastolic and systolic function
of the intact heart, most often, from transgenic mouse
models. One major problem associated with in situ studies
is that secondary changes in myocardial structure and other
myocyte proteins besides the mutant one can complicate the
interpretation of results. Many in vitro studies have used the
thin filament sliding motility assay that tracks the move-
ment of fluorescently labeled actin filaments (unregulated
or reconstituted with regulatory proteins) generated by
myosin molecules adsorbed onto a fixed surface. Actin-
activated ATPase activity can also be measured in isolated
proteins. One should consider that these assays probe the
acto-myosin transduction cycle and its regulation under
unloaded conditions and in the absence of the structured
sarcomere environment. In addition, all these assays relay
on the quality of the protein preparations and this,
especially for myosin, may be problematic.
In fact, the source and quality of material for in vitro and in
situ studies has likely been a major reason for the variability
between studies of the mutant proteins. Limited purification
methods of small amounts of myosin from human biopsies may
have resulted in inadequate experimental material in the earliest
studies on the R403Qmutation [44, 34]. The source of material
in subsequent studies has largely been either recombinant
proteins (either studied in vitro or exchanged—or expressed
by transfection—into a variety of muscle preparations) or
engineered mouse models.
It now appears that using recombinant techniques to
introduce cardiac myosin mutations into truncated or
smooth muscle myosins or into fast-type mouse and rat
myosins, even if technically perfect, may not faithfully
mimic the human mutant myosin [34, 35]. While these
molecules may be useful for investigating the physiology of
the sarcomere, they may produce misleading results in the
context of identifying the disease mechanisms in HCM.
Work with recombinant proteins other than myosin has also
shown that the effect of a mutation is often very context-
dependent, being influenced by isoform type, species of
origin, and posttranslational modifications especially phos-
phorylation [5, 13]. Investigations of the effects of
admixture of mutant and wild-type proteins have shown
the importance of studying 50:50 mixtures, as are expected
in a heterozygous disease [49, 52, 51].
A number of over-expressing transgenic mouse models
and some gene-targeted lines have been created and
characterized (for a review see Shephard and Semsarian
“Role of animal model in HCM research” in this issue).
These models have had great impact on our knowledge of
disease–gene relationships and HCM pathogenesis. More-
over, the use of novel inducible transgenic mouse models of
HCM (the transgene of interest can be turned on at
preselected times) will greatly facilitate our understanding
of the primary functional effects of HCM mutations and the
factors which may induce and modify the progression of
the disease. Not all of these transgenic models, however,
have mimicked the human HCM phenotype and in some
instances, this may reflect a stoichiometry of mutant/wild-
type protein that is not representative of human HCM. In
many transgenic HCM models, the biophysical changes at
the level of the myofilament closely mirror those seen in
other experimental systems, but the whole organ phenotype
444 J. of Cardiovasc. Trans. Res. (2009) 2:441–451
does not mirror human disease (e.g., no hypertrophy or
increased risk of sudden death), perhaps reflecting differ-
ences in adaptive/maladaptive remodeling [62, 29].
The above considerations emphasize that the application
of in vitro and transgenic results to human disease requires
careful study and direct validation in human cardiac tissue
samples.
Direct Investigation of Sarcomere Function in Heart
Samples from HCM Patients
In spite of many studies of mutations in experimental models of
HCM, there have been few reports to date that actually directly
document the functional abnormalities present in human HCM
heart muscle. The most significant reasons for this are the
limited availability of affected tissue and of suitable control
human myocardium. An important advancement for the
definition of the structural and functional changes present in
human HCM tissue can be the creation of large banks of
affected and control tissue through the collaboration of a
number of centers for HCM studies. This will provide
researchers access to cardiac tissue harvested from fully
characterized patients undergoing cardiac surgery.
Cardiac muscle cell contraction and relaxation are
governed by the interplay between two macromolecular
systems: (1) membrane-bound Ca2+ transport proteins,
responsible for the Ca2+ signal that switches contraction
on and off and (2) sarcomere proteins, responsible for
passive and active force generation and contraction regula-
tion by Ca2+. Together, these macromolecular systems
determine the extent and kinetics of cardiac cell contraction
and relaxation and both expend large amounts of energy. To
separate their roles in muscle function, skinned cardiac
muscle preparations are employed. In these preparations,
cell and sarcoplasmic reticulum membranes (and thus all
Ca2+ handling systems) are removed, allowing investigators
to experimentally control [Ca2+] and focus on the process
of force generation and relaxation at the sarcomere level.
Skinned myocardial strips isolated from human hearts
are the conventional preparations used to measure changes
in fundamental indices of muscle performance accompa-
nying alterations of human cardiac sarcomeric proteins
(e.g., [18, 40, 42, 43]). These preparations, however, have
important limitations. Because cardiac strips are cut from
bulk muscle and myocytes are not perfectly aligned along
the axis of the strip, these preparations may include regions
of muscle which lack mechanical continuity. In addition,
the fractional volume occupied by sarcomeres in cardiac
strips may vary depending on the tissue samples from
which they are isolated. These factors can be a large source
of variability in mechanical parameters and significantly
complicate the interpretation of the functional effects of
sarcomeric protein mutations.
Fig. 2 Skinned cardiac myocytes (a and b) and isolated cardiac
myofibrils (c and d). Calibration bars in all panels are 10 μm. These
preparations can be obtained in large amounts from small fresh or
frozen human cardiac samples (see myocyte and myofibril suspen-
sions in a and c, respectively) and can be used for mechanical
experiments after mounting in force recording apparatuses (b and d).
In b, a single human ventricular myocyte is glued between a force
transducer and a piezo-electric motor (courtesy Dr. Jolanda van der
Velden). In d, upper panel, a single myofibril is mounted between a
cantilever force transducer and a glass microtool connected to a
length-control motor. As better shown in the bottom panel, myofibrils
are formed of single rows of serially arranged sarcomeres
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Mechanically isolated skinned myocytes [71, 67] and
single myofibrils [46] are a significant advance in the
ability to directly measure changes in the mechanical
performance of human cardiac muscle with altered sarco-
meric proteins. These preparations can be obtained in
significant amounts even from small fresh or frozen cardiac
samples (Fig. 2) and enable direct correlations between in
vivo hemodynamic patient characteristics and functional
properties of the sarcomere [9].
Recent force measurements in mechanically disrupted
Triton-permeabilized cardiomyocytes from HCM patients
carrying truncation mutations in cMyBP-C show, compared
with controls, a decrease in maximal isometric force per
cross-sectional area and an increase in myofilament Ca2+-
sensitivity [68, 25]. These changes are accompanied by
reduction (25–35%) in myofibril cMyBP-C content, a direct
consequence of the truncation mutations. Though the
increased Ca2+-sensitivity may be a secondary consequence
of altered phosphorylation levels of the sarcomeric proteins
[68], previous functional studies, in which cMyBP-C has
been partially extracted from skinned animal cardiomyo-
cytes, indicate that the observed reduction in protein
content in human HCM myocytes may be sufficient to
cause both the observed mechanical changes [22, 30].
Isolated cardiac myofibrils, as a model for mechanical
kinetics experiments, hold some advantage over larger prepa-
rations [47, 59]. Single myofibrils are the smallest units of the
contractile apparatus of striated muscle that retain the
organized myofilament lattice and entire ensemble of associ-
ated proteins. Miniaturized mechanical methods measuring
myofibril force have been developed in the past years.
Because of their small size (the diffusion distances are <
2 µm), single myofibrils equilibrate with bathing solutions in
less than 1 ms, and the myofilament lattice can be effectively
clamped at any desired composition by flowing streams of
solution over the preparation. Rapid solution switching
(Fig. 3a), originally developed for other biological applications
[54], can thus be used in isolated myofibrils (1) to abruptly
change the concentration of Ca2+ and investigate force
activation and relaxation kinetics ([64], see Fig. 3b), (2) to
abruptly change the concentrations of substrate (MgATP) and
products (Pi and MgADP) of the acto-myosin ATPase and
dissect some specific steps of the crossbridge chemo-
mechanical cycle [63].
A recent myofibril study [7] is the first to directly
examine the mechanical kinetics of cardiac sarcomeres
from a patient affected by HCM. The patient carried the
severe R403Q mutation in the β-MyHC. In the R403Q
myofibrils, maximal isometric tension was lower—or
tended to be lower—relative to control groups, whereas
the kinetics of tension development and relaxation were
faster (Fig. 4), indicative of faster crossbridge turnover rate,
an apparent (but probably not real) gain of protein function.
The observation that the rate constant of the initial, slow,
isometric phase of relaxation (slow kREL) markedly in-
creased in the R403Q myofibrils compared with controls is
rather striking and shows that the mutation increases the
k
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Fig. 3 Fast solution-switching to measure force activation and
relaxation kinetics in human cardiac myofibrils. a Experimental setup.
The myofibril is mounted horizontally between two glass microtools.
One tool is connected to a length-control motor that can produce rapid
(<1 ms) length changes. The second tool is a calibrated cantilevered
force probe. Force is measured from the deflection of the image of the
force probe projected on a split photodiode. Myofibrils are maximally
activated and fully relaxed by rapid translation between two
continuous streams of relaxing (pCa=−log10 [Ca2+]=8.0) and activat-
ing (pCa 4.5) solutions flowing from a double-barreled glass pipette
placed at a right angle to the preparation. Solution change after the
start of the pipette movement is complete within 10 ms [64]. To
induce Ca2+-activated force development, the pipette is switched from
the left position (flow configuration drawn in dashed lines) to the right
(solid lines). To induce relaxation, the movement is reversed.
Modified from [59]. b Representative force response (top trace) of a
human atrial myofibril maximally activated and fully relaxed by fast
solution-switching (pCa changes at arrows as indicated). Initial
sarcomere length 2.2 μm, temperature 15°C. Fast length changes
(bottom trace) are applied to the myofibril under conditions of steady
tension generation. kACT is the rate constant of tension generation
following fast Ca2+ activation; kTR is the rate constant of tension
redevelopment following the rapid length perturbation; kREL are the
rate constants of the biphasic tension relaxation following fast Ca2+
removal (see Fig. 4e)
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Fig. 4 Tension generation and relaxation in control donor and R403Q
left ventricular myofibrils. Data from [7] a representative tension
responses (top traces) of donor and R403Q myofibrils maximally
activated and fully relaxed by fast solution-switching (pCa changes at
arrows as indicated). Temperature 15°C. Fast length changes (bottom
traces) are applied to the myofibrils under conditions of steady tension
generation. b Mean values of maximal tension (P0) for the donor
(white column) and R403Q (red column) myofibrils. Bars on top of
columns are SEM; the number of myofibrils is given on top of SEM
bars. c The time course of tension activation following sudden [Ca2+]
increase of the donor and R403Q myofibrils shown in (a) are
superimposed on a faster time base after normalization for maximal
tension. (d) Mean values of kACT for the donor (white column) and
R403Q (red column) myofibrils. Bars and numbers as in (b). e
Tension relaxation kinetics following sudden Ca2+ removal; same
traces as in a superimposed on a faster time base after normalization
for maximal tension. The rate constant of the early slow-force decline
(slow kREL) is estimated from the slope of the regression line fitted to
the tension trace normalized to the entire amplitude of the tension
relaxation transient. The rate constant for the final fast phase of
tension decline (fast kREL) is estimated from mono-exponential fit. f
Mean values of slow kREL for the donor (white column) and R403Q
(red column) myofibrils. Bars and numbers as in b
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Fig. 5 Reaction pathway for acto-myosin ATPase and energy
transduction cycle. a The reaction pathway can be described as a
series of coupled biochemical and mechanical events. The structure of
the myosin head (depicted as in Fig. 1 with the light chain binding
domain that can move like a lever arm relative to the actin-binding,
catalytic domain) is designed to achieve the efficient conversion of
biochemical energy. ATP binding to a myosin head (M) causes a
rapid, almost irreversible dissociation of the myosin head from actin
(A). Following detachment from actin, the ATP is hydrolyzed to ADP
and inorganic phosphate (Pi) both of which remain tightly bound to
the myosin head. The free energy of ATP hydrolysis is not released
but remains within the structure of the M.ADP.Pi complex. The
hydrolysis is, in fact, accompanied by a major conformational change
that represents a repriming of the power stroke; both the hydrolysis
and the conformational change are reversible. ADP and Pi will remain
bound to the myosin head until the myosin binds to an actin site. The
affinity of M.ADP.Pi for actin is significantly higher than that of M.
ATP. If an actin site is within reach of the myosin head, it will bind
rapidly and reversibly to the actin site. The interaction of the M.ADP.
Pi complex with actin can promote a major change in conformation
(the power stroke) which is accompanied by the dissociation of Pi. If
the filaments carry an external load (e.g., isometric conditions), then
the power stroke results in the distortion of an elastic element. The
location of the elastic element is unknown and is drawn here, for
simplicity, as part of the S2 region connecting the myosin head to the
rod. The dissociation of Pi is a reversible event and Pi can rebind to
reverse the power stroke. The final step of the chemo-mechanical
coupling is a strain-dependent mechanism of ADP release leading to
an AM complex rapidly dissociated by new ATP binding. ADP release
can be very fast if the external load on the filaments is small while it is
much slower under high loads (isometric conditions). The features of
this transition likely differ between myosin designed for efficient fast
shortening vs efficient load bearing. In this generally accepted
scheme, transitions of crossbridges from force-generating to non-
force-generating states involved in isometric force relaxation comprise
both forward (ADP release and ATP binding) and backward (Pi
rebinding and reversal of the power stroke) steps. However, myofibril
slow (isometric) kREL, measured in the absence of Pi (as in the case of
[7]), only probes forward detachment transitions that lead to ATP
hydrolysis steps. b 2-state crossbridge scheme. On the basis of
myosin’s binding affinity for actin, two general categories of cross-
bridges can be defined: AMno force represents all weak binding states
(detached states M.ATP, M.ATP.Pi in rapid equilibrium with AM.ATP,
AM.ADP.Pi) and AMforce all strong binding states (AM, AM.ADP).
The transition from the non-force-generating states to the force-
generating states has an apparent rate constant fapp, whereas gapp
describes the return to the non-force-generating states by means of
ADP release and ATP binding. The apparent rate constant for the
reverse transition f’app that depends on [Pi] can be neglected under the
conditions of the study by [7] (absence of Pi) and myofibril slow
kREL≈gapp. In the model, the energy cost of tension generation
(ATPase/tension ratio) is proportional to gapp. Given slow kREL≈gapp,
the increase in slow kREL associated with the R403Q mutation predicts
a 3-fold increase in the energy cost of tension generation in R403Q
sarcomeres [7]
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apparent rate of dissociation of myosin from actin under
isometric conditions (gapp; see Fig. 5). Analysis with simple
crossbridge models of sarcomere force generation indicates
that the increase in gapp associated with the R403Q mutation
accounts almost entirely for the faster isometric crossbridge
turnover (faster rate of force generation) and the lower
maximal isometric tension. The marked increase in gapp under
isometric conditions is expected to greatly increase the
overall tension cost in the HCM heart (Fig. 5b) consistent
with a wide range of biochemical [27] and NMR-based
studies in both HCM patients [11] and animal models [58,
26, 19] of the disease. Though only direct measurements of
ATPase activity under isometric conditions (see [43] for
possible methods) can definitely confirm this conclusion, the
results strongly support the idea that the R403Q mutation
leads to inefficient ATP utilization for tension generation.
The finding that relaxation kinetics are faster in the
R403Q myofibrils than in the controls is apparently
inconsistent with clinical evidence of diastolic dysfunction
associated with HCM [20]. In the whole heart, however,
multiple mechanisms determine the time course of tension
relaxation while in the myofibril experiments we focus
solely on the sarcomeric determinants of the relaxation
process independent of disease-associated secondary
changes occurring in other cell functions and sarcomere
ionic microenvironment. For example, in intact cardiac
myocytes, the mechanisms related to [Ca2+] reduction in
the myoplasm are important determinants of the time course
of force relaxation. In the intact myocardium, compromised
energetics may slow down relaxation by altering the Ca2+
transport function needed for Ca2+ removal from the
myoplasm. Compromised energetics may also alter the
ionic microenvironment of contractile proteins and this, in
turn, can impair force relaxation.
Myofibril studies on HCM patients can represent an
important advance both with respect to conclusions about
specific mutations at the level of the cardiac crossbridge
cycle and its regulation and, as a methodology, to provide a
unique and more biophysically proximal phenotypic char-
acterization of HCM.
Conclusions
Though direct analysis of the altered functional character-
istics of HCM human cardiac sarcomeres has so far lagged
behind the in vitro and mouse studies, initial results seem to
validate current pathogenetic hypotheses based on a
number of studies in experimental HCM models [3]. It is
encouraging that these hypotheses implicate targets that can
be much more amenable to pharmacological alteration than
might have been expected from the initial finding of
structural alteration of the myofilament proteins. For
example, many existing agents have been developed for
amelioration of myocardial energetics (typically, in the
context of ischemic heart disease), e.g., by switching
substrate utilization. Experimental evidence in rodent
models suggests that agents, to decrease myofilament
calcium sensitivity (not yet available in man), could also
be expected to have markedly beneficial effects particularly
on propensity to arrhythmia [4].
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